Mieloma Múltiplo: a propósito de um caso raro de gamapatia biclonal IgD/lambda – Abordagem diagnóstica e atitudes terapêuticas
Palavras-chave:
mieloma múltiplo, etiologia, diagnóstico, complicações, prognóstico, tratamentoResumo
Os AA. descrevem o caso clínico de um doente com o diagnóstico de mieloma múltiplo, realizado
através do doseamento das imunoglobulinas séricas, da imunofixação das proteínas séricas e urinárias
e do mielograma.
A propósito deste caso clínico efectuam uma breve revisão da literatura, dando especial ênfase à
etiologia, características clínicas, laboratoriais e imagiológicas, complicações específicas, factores de
prognóstico, terapêutica actualmente utilizada e eventuais abordagens terapêuticas no futuro,
relativamente a esta entidade clínica.
Downloads
Referências
Kyle RA. Plasma cell disorders. In: Goldman L et al. Cecil Textbook of Medicine. 21th ed. Philadelphia WB Saunders Company, 2000; 13 (181): 977-987.
Drach J et al. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126 (8): 441-7.
Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukaemia. Leuk Res 2000; 24 (8): 681-703.
Gado K et al. Role of Interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 2000; 24 (4); 195-209.
Kelly T et al. Matrix metalloproteinases in multiple mieloma. Leuk Lymphoma 2000 ; 37 (3-4) : 273-281.
Beaudreuil J, Orcel P. Bone hyperresorption in multiple myeloma. Press Med 2000; 29 (9): 492-497.
Longo DL. Plasma cell disorders. In : Braunwald E et al. Harrison´s Principles of Internal Medicine. 14th ed. New York. McGraw-Hill 1998; 114: 712-724.
Barlogie B et al. Plasma cell myeloma. In: Beutler E. et al. Williams Hematology. 6th ed. New York. McGraw-Hill 2001; 106:1279-1300.
Cathomas G. Human herpes virus 8: a new virus discloses its face. Virchows Arch 2000; 436 (3): 195-206.
Chesi M et al. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol 2000; 11 suppl 1: 131-135.
Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336 (23): 1657-1663.
Treon SP et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 2000; 11 Suppl 1: 107-111.
Boccadoro M, Pileri A. Diagnosis, prognosis and standard treatment of multiple myeloma. Hematol Oncol Clin North America 1997; 11 (1): 111-125.
Sinohara H. Does catalytic activity of Bence-Jones proteins contribute to the pathogenesis of multiple mieloma?. Appl Biochem Biotechnol 2000; 83 (1-3); 85-92; discussion 93-4, 145-153.
Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer 2000; 88 (Suppl 12): 3022-3032.
Clezardin P et al. Mechanisms of action of biphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 2000; 67 (1): 22-29.
Clezardin P. Bone hyperresorption in bone metastases. Presse Med 2000; 29 (9): 487-491.
Rodman GD Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer Sup. 1997; 80 (8): 1557-1562.
Halczuk I et al. Myelomatous meningitis : a case report. Neurol Neurochir Pol 1999 ; 33 (6): 1425-1433.
Dimopoulos MA et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma.Blood 2000; 96 (6): 2037-2044.
Kyle RA. The role of high dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol 2000; 11 Suppl 1: 55-58.
Blad J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?. Med Oncol 2000; 17 (2): 77-84.
Davies FE, Anderson KC. Novel therapeutic targets in multiple myeloma. Eur J Haematol 2000; 64 (6): 359-367.
Shtil AA et al. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma 2000; 38 (1-2): 59-70.
Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247 (5): 521-534.
Hajek R, Butch AW. Dendritic cell biology and the application of dendritic cells toimmunotherapy of multiple myeloma. Med Oncol 2000; 17 (1): 2-15.
Dimopoulos MA et al. Thalidomide and dexamethasone combination for refractory multiplemyeloma. Ann Oncol 2001; 991-995.
Attal M, Harousseau JL. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol 1999; 12 (1-2) 171-191.
Gahrton G, Bjorkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med 2000; 248 (3): 185-201.
Riera L, Koziner B. Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells. Medicina (B Aires) 2000; 60 (2): 259-269.
Attal M et al. Single versus double transplant in myeloma: a randomized trial of the “Inter Group Grancais du myelome”. France.
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
